Dipping in 2020
30/12/19 -"We have re-worked our financial model after some initial adjustments. Our general view on the company remains broadly unchanged, but the incorporation of the AR's full set of figures and a stronger ..."
Pages
72
Language
English
Published on
30/12/19
You may also be interested by these reports :
11/11/26
The Q3 sales and profitability met expectations; however, a slight guidance downgrade disappointed investors. Healthy growth in all sub-segments was ...
09/11/26
Qiagen’s Q3 results exceeded management’s guidance, with sales primarily driven by Sample Technologies and Genomics/NGS. However, challenges in US ...
06/11/26
In early September 2026, we suggested that the 5 lean years for MedTechs performance had maybe reached an end. Bingo. The following chart confirms ...
06/11/26
S&N reported Q3 26 revenue of $1,551m (+3.4% organic), in line with consensus. Sports Medicine & ENT led (+7.9%), but continued weakness in US Knees ...